Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,194 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapy-Related Acute Promyelocytic Leukemia: Case Series and Current Insights.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Morelli R, Rossi T, Neri A, Morabito F, Gentile M, Vigna E. Bruzzese A, et al. Among authors: neri a. Eur J Haematol. 2025 Jan;114(1):195-198. doi: 10.1111/ejh.14327. Epub 2024 Oct 13. Eur J Haematol. 2025. PMID: 39397152 Free PMC article.
Venetoclax in acute myeloid leukemia.
Bruzzese A, Martino EA, Mendicino F, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: neri a. Expert Opin Investig Drugs. 2023 Apr;32(4):271-276. doi: 10.1080/13543784.2023.2193679. Epub 2023 Mar 23. Expert Opin Investig Drugs. 2023. PMID: 36933006 No abstract available.
Acalabrutinib in chronic lymphocytic leukemia.
Martino EA, Bruzzese A, Vigna E, Iaccino E, Mendicino F, Lucia E, Olivito V, Filippelli G, Neri A, Morabito F, Gentile M. Martino EA, et al. Among authors: neri a. Expert Opin Pharmacother. 2023 Apr;24(5):545-549. doi: 10.1080/14656566.2023.2194486. Epub 2023 Mar 23. Expert Opin Pharmacother. 2023. PMID: 36943916 No abstract available.
Zanubrutinib for the treatment of chronic lymphocytic leukemia.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: neri a. Expert Opin Pharmacother. 2023 Sep-Dec;24(13):1409-1413. doi: 10.1080/14656566.2023.2229734. Epub 2023 Jun 26. Expert Opin Pharmacother. 2023. PMID: 37350553 No abstract available.
Glasdegib for the treatment of acute myeloid leukemia.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Fimognari F, Neri A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: neri a. Expert Opin Pharmacother. 2023 Sep-Dec;24(14):1537-1543. doi: 10.1080/14656566.2023.2232301. Epub 2023 Jul 3. Expert Opin Pharmacother. 2023. PMID: 37392098
Tagraxofusp in myeloid malignancies.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Imovilli A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: neri a. Hematol Oncol. 2024 Jan;42(1):e3234. doi: 10.1002/hon.3234. Epub 2023 Oct 17. Hematol Oncol. 2024. PMID: 37846131 Review.
Ivosidenib in acute myeloid leukemia.
Bruzzese A, Labanca C, Martino EA, Mendicino F, Lucia E, Olivito V, Neri A, Imovilli A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: neri a. Expert Opin Pharmacother. 2023 Sep-Dec;24(18):2093-2100. doi: 10.1080/14656566.2023.2272659. Epub 2024 Jan 5. Expert Opin Pharmacother. 2023. PMID: 37874005 Review.
Potential of BGB-11417, a BCL2 inhibitor, in hematological malignancies.
Bruzzese A, Martino EA, Labanca C, Mendicino F, Lucia E, Olivito V, Neri A, Morabito F, Vigna E, Gentile M. Bruzzese A, et al. Among authors: neri a. Expert Opin Investig Drugs. 2024 Feb;33(2):73-77. doi: 10.1080/13543784.2024.2309873. Epub 2024 Jan 26. Expert Opin Investig Drugs. 2024. PMID: 38264792 No abstract available.
1,194 results